Novartis Aktie
101,86
EUR
+0,56
EUR
+0,55
%
97,48
CHF
+0,66
CHF
+0,68
%
Kursziele der Novartis-Aktie in CHF
Das durchschnittliche Kursziel beinhaltet alle Analysen eines Analysten und nicht nur die jeweils aktuellste Analyse, die im Chart dargestellt wird.
Diese Analysten bewerten die Novartis-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| Deutsche Bank AG | 110,00 CHF | +12,84% | 06.03.2025 | |
| JP Morgan Chase & Co. | 95,00 CHF | -2,54% | 25.02.2025 | |
| Bernstein Research | 115,00 CHF | +17,97% | 20.02.2025 | |
| UBS AG | 104,00 CHF | +6,69% | 13.02.2025 | |
| Goldman Sachs Group Inc. | 98,00 CHF | +0,53% | 11.02.2025 | |
| DZ BANK | - | - | 03.02.2025 | |
| Jefferies & Company Inc. | 100,00 CHF | +2,59% | 31.01.2025 | |
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 86,00 CHF | -11,78% | 07.01.2025 | |
| Barclays Capital | 85,00 CHF | -12,80% | 21.11.2024 |
Werbung
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| APONTIS PHARMA | 0 | 0 | 0 | - | - |
| AstraZeneca PLC | 6 | 3 | 0 | 139,66 GBP | +21,97% |
| Bayer | 1 | 8 | 0 | 24,88 EUR | +14,65% |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| EVOTEC SE | 2 | 2 | 1 | 9,68 EUR | +64,21% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| GSK PLC Registered Shs | 2 | 6 | 1 | 16,62 GBP | +13,19% |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 7 | 1 | 0 | 180,57 EUR | +43,31% |
| Mylan N.V. | 0 | 0 | 0 | - | - |
| Novartis AG | 3 | 5 | 1 | 99,12 CHF | +1,68% |
| Pfizer Inc. | 3 | 3 | 0 | 30,20 USD | +22,27% |
| Roche AG (Genussschein) | 3 | 3 | 3 | 285,88 CHF | +2,21% |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Sanofi S.A. | 6 | 3 | 0 | 115,50 EUR | +15,99% |
| STADA | 0 | 0 | 0 | - | - |
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
| Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Warner Chilcott plc | 0 | 0 | 0 | - | - |